A phase 1/2 study of tazemetostat, a potent inhibitor of EZH2, either as a single agent or combined with the steroid, prednisolone, is ongoing in DLBCL patients (NCT01897571). Here, EZH2 is linked to diffuse large B-cell lymphoma.